BRAF基因突变型甲状腺癌患者血清TSH TgAb MK表达及临床意义

doi:10.3969/j.issn.1006-6233.2023.09.09

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1393 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the levels of serum thyrotropin (TSH), thyroglobulin antibody (TgAb) and intermediate factor (MK) in patients with thyroid cancer (TC) with the B1 (BRAF) gene homology of anti-mouse sarcoma virus, and to analyze the diagnostic value of TSH in patients with TC. Methods: 83 cases BRAF gene mutant TC patients admitted to our hospital from January 2021 to January 2022 were selected as the mutation group, and 83 cases BRAF gene wild-type TC patients in the same period were selected as the wild group following the principle of 1∶1 allocation. Demographic data, clinicopathological features, serum TSH, TgAb and MK levels of the two groups were analyzed. The influencing factors of mutant TC were analyzed by Logistic regression equation. The diagnostic value of each index on mutant TC was evaluated and its influence on the risk of mutant TC were analyzed. Results: There were significant differences in tumor stage, capsule invasion, tumor number, cervical lymph node metastasis, central lymph node metastasis and serum TSH, TgAb and MK levels between the two groups (P<0.05). Serum TSH, TgAb and MK levels were positively correlated with BRAF gene mutation (P<0.05). Increased serum TSH, TgAb and MK levels were the risk factors for BRAF mutant TC (P<0.05). The AUC of serum TSH, TgAb and MK in the diagnosis of BRAF mutant TC was greater than that of single diagnosis (P<0.05). The risk of BRAF gene mutation TC in high TSH, TgAb and MK expression group was 1.500, 1.625 and 2.617 times higher than that in low expression group (P<0.05). Conclusion: The serum levels of TSH, TgAb and MK in patients with BRAF mutant TC are elevated. The combined detection of TSH, TGAb and MK levels is of certain diagnostic value for BRAF mutant TC.

Key words： Thyroid cancer Anti-murine sarcoma virus oncogene homologue B1 Thyroid-stimulating hormone Thyroglobulin antibodies Intermediate factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Peihong
	AN Liyun
	SHAO Rubin
	et al

Cite this article:

LIU Peihong,AN Liyun,SHAO Rubin, et al. Expression and Clinical Significance of Serum TSH TgAb and MK in Patients with BRAF Gene Mutant Thyroid Cancer[J]. HeBei Med, 2023, 29(9): 1452-1458.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.09.09 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I9/1452

[1] Lam A K.Papillary thyroid carcinoma:current position in epidemiology,genomics,and classification[J].Methods Mol Biol,2022,2534(1):1-15.
[2] Chan WWL,Kwong DLW.Radioactive iodine for papillary thyroid carcinoma[J].Methods Mol Biol,2022,2534(1):225-241.
[3] 杜春平,廖芝玲,吴圣明,等.BRAF基因突变型甲状腺乳头状癌组织基因表达及肿瘤微环境的变化[J].山东医药,2020,60(28):25-28.
[4] Yildirim Simsir I,Cetinkalp S,Kabalak T.Review of factors contributing to nodular goiter and thyroid carcinoma[J].Med Princ Pract,2020,29(1):1-5.
[5] Pan M,Li Z,Jia M,et al.Combination of stimulated thyroglobulin and antithyroglobulin antibody predicts the efficacy and prognosis of ¹³¹I therapy in patients with differentiated thyroid cancer following total thyroidectomy:a retrospective study[J].Front Endocrinol (Lausanne),2022,13(1):857057-857067.
[6] Yang KD,Wang Y,Zhang F,et al.CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer[J].Mol Cell Biochem,2022,477(11):2493-2505.
[7] Luster M,Aktolun C,Amendoeira I,et al.European perspective on 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:proceedings of an interactive international symposium[J].Thyroid,2019,29(1):7-26.
[8] Hu J,Yuan IJ,Mirshahidi S,et al.Thyroid carcinoma:phenotypic features,underlying biology and potential relevance for targeting therapy[J].Int Mol Sci,2021,22(4):1950-1960.
[9] Wei X,Wang X,Xiong J,et al.Risk and prognostic factors for BRAFV600E mutations in papillary thyroid carcinoma[J].Biomed Res Int,2022,1(10):49-59.
[10] Bae MR,Nam H,Roh JL,et al.Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma[J].Endocrine,2022,75(2):487-494.
[11] Rianto BUD,Wibowo AS,Herdini C.The difference in thyroid stimulating hormone levels between differentiated carcinoma and benign enlargement[J].Int Arch Otorhinolaryngol,2020,24(1):e73-e79.
[12] Landenberger GMC,De Souza Salerno ML,Golbert L,et al.Thyroglobulin antibodies as a prognostic factor in papillary thyroid carcinoma patients with indeterminate response after initial therapy[J].Horm Metab Res,2021,53(2):94-99.
[13] Zhang Y,Tang J,Zhou X,et al.Diagnostic accuracy of midkine for hepatocellular carcinoma:a meta-analysis[J].Mol Genet Genomic Med,2020,8(2):1071-1081.
[14] Hernandez BY,Rahman M,Loo Lwm,et al.BRAFV600E,hypothyroidism,and human relaxin in thyroid carcinogenesis[J].Cancer Res Clin Oncol,2021,147(1):183-194.